(Q41064722)

26 September 2017

title

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance (English)

1 reference

26 September 2017

0 references

6

John H Boyd

1 reference

26 September 2017

Keith R Walley

1

1 reference

26 September 2017

Gordon A Francis

2

1 reference

26 September 2017

Steven M Opal

3

1 reference

26 September 2017

Evan A Stein

4

1 reference

26 September 2017

James A Russell

5

1 reference

26 September 2017

language of work or name

English

0 references

publication date

7 August 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

26 September 2017

published in

1 reference

26 September 2017

volume

192

1 reference

26 September 2017

issue

11

1 reference

26 September 2017

page(s)

1275-1286

1 reference

Distribution and kinetics of lipoprotein-bound lipoteichoic acid

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The Candida albicans phospholipomannan is a family of glycolipids presenting phosphoinositolmannosides with long linear chains of beta-1,2-linked mannose residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Molecular biology of inflammation and sepsis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Crosstalk between reverse cholesterol transport and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Candida albicans phospholipomannan, a new member of the fungal mannose inositol phosphoceramide family

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Roles of plasma lipid transfer proteins in reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Bioinformatics of the TULIP domain superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI) is highly conserved

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Murine bactericidal/permeability-increasing protein inhibits the endotoxic activity of lipopolysaccharide and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Apolipoproteins modulate the inflammatory response to lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Distribution and kinetics of lipoprotein-bound endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

In vivo protection against endotoxin by plasma high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Apolipoprotein E suppresses the type I inflammatory response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Apolipoprotein E-mediated immune regulation in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Hyperlipoproteinemic low-density lipoprotein receptor-deficient mice are more susceptible to sepsis than corresponding wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Bridging lipid metabolism and innate host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Candidate gene association resource (CARe): design, methods, and proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Lipids. Antibodies against PCSK9--a new era of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Scavenger receptor class a plays a central role in mediating mortality and the development of the pro-inflammatory phenotype in polymicrobial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

APOε4 is associated with enhanced in vivo innate immune responses in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Haplotype analysis of ApoAI gene and sepsis-associated acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The effect of insulin on circulating PCSK9 in postmenopausal obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Acute TSH stimulation in vivo does not alter serum PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Reduction of circulating cholesterol and apolipoprotein levels during sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The relationship between plasma cholesterol, amino acids and acute phase proteins in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Genetic and metabolic determinants of plasma PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes melli

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Association between statins given in hospital and mortality in pneumonia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Regulation of the uptake of high-density lipoprotein-originated cholesteryl ester by HepG2 cells: role of low-density lipoprotein and plasma lipid transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Low-density lipoprotein cholesterol reduction by inhibition of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201505-0876CI

10.1164/RCCM.201505-0876CI

21 January 2018

Identifiers

DOI

1 reference

26 September 2017

1 reference